Canada's dedicated kidney licensing and commercialization partner — closing the gap between global innovation and Canadian patients.
Discover KidneraWho we are
To ensure that no breakthrough kidney therapy bypasses Canada, and that every Canadian patient benefits from global renal innovation.
To serve as Canada's dedicated kidney licensing and commercialization partner, accelerating access to innovative therapies through scientific credibility, regulatory expertise, and a nationally embedded nephrology network.
Leadership
Chief Executive Officer
Chief Finance Officer/Chief Business Officer
Chief Medical Officer
Chief Commercial Officer
The gap
Canadians living with chronic kidney disease
Canadian specialty pharma market
Of novel renal therapies not yet in Canada
US biotechs are developing transformative renal therapies — yet most never reach Canadian patients. Health Canada pathways, provincial payer complexity, and the absence of a dedicated renal commercialization partner create a persistent gap. Kidnera exists to close it.
Market timing
Centralized provincial formulary structures deliver recurring, contracted payer revenue once listed — unlike fragmented US payer environments.
Health Canada accepts ICH data packages; a well-executed NDS can proceed in parallel with or shortly after FDA approval.
Canadian nephrologists are actively seeking access to novel therapies already approved or in late-stage development in the US.
No dedicated renal licensing platform currently exists in Canada. This window is open now — and will not stay open.
Canadians covered by public drug plans
Provinces — each a structured formulary
Typical Health Canada review timeline
Revenue left on table by US biotechs today
What we offer
You focus on innovation. We focus on Canada.
Dr. Navdeep Tangri's national KOL standing opens doors across every major nephrology centre in Canada. Advisory boards, investigator-initiated studies, and CME programs are immediately accessible.
We navigate Health Canada NDS/SNDS filings, CDR submissions, and pCPA negotiations. We turn complex Canadian payer structures into predictable revenue timelines.
Jeff Marchand's specialty pharma launch experience at Otsuka covers the full arc — from pre-launch HCP engagement to post-listing demand generation and patient support.
Lee Courchesne's medical education infrastructure provides unmatched reach into Canadian HCPs. We don't need to build relationships — we already have them.
We are not a generalist partner across 10 therapeutic areas. We are renal specialists. Your asset gets our full attention — not a line item in a broad portfolio.
Our licensing model means our success is tied directly to yours. We are motivated partners, not a fee-for-service operator.
Get in touch
Interested in partnering with Kidnera? We'd love to hear from you.
info@kidnera.com